Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Elisa K. Chan, MD

Advertisement

Articles by Elisa K. Chan, MD

Dr. Chan on Improving Mammography Screening Rates With Signed Letters

ByElisa K. Chan, MD
September 8th 2014

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

Advertisement

Latest Updated Articles

  • Dr. Chan on Improving Mammography Screening Rates With Signed Letters
    Dr. Chan on Improving Mammography Screening Rates With Signed Letters

    September 8th 2014



Advertisement
Advertisement

Trending on OncLive

1

Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance

2

Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma

3

Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026

4

Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML

5

Real-World Data Highlight Prognostic Value of ctDNA Testing in Lymphomas

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us